Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.

Cell systems | 2018

Clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.

Pubmed ID: 30007540 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-rabbit IgG, HRP-linked Antibody (antibody)

RRID:AB_2099233

This polyclonal secondary targets IgG

View all literature mentions

Mouse Anti-ERK-1 / ERK-2, diphospho Monoclonal Antibody, Unconjugated, Clone MAPK-YT (antibody)

RRID:AB_477245

This monoclonal targets MAP Kinase, Activated (Diphosphorylated ERK-1&2)

View all literature mentions

Anti-MAP Kinase (ERK-1, ERK-2) antibody produced in rabbit (antibody)

RRID:AB_477216

This polyclonal targets MAP Kinase (ERK-1 ERK-2) antibody produced in rabbit

View all literature mentions

Mel JuSo (cell line)

RRID:CVCL_1403

Cell line Mel JuSo is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

A-375 (cell line)

RRID:CVCL_0132

Cell line A-375 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SK-MEL-2 (cell line)

RRID:CVCL_0069

Cell line SK-MEL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions